Cardiovascular Risk Reduction With Liraglutide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
Diabetes Care 2020 May 04;[EPub Ahead of Print], JB Buse, SC Bain, JFE Mann, MA Nauck, SE Nissen, S Pocock, NR Poulter, RE Pratley, M Linder, T Monk Fries, DD Ørsted, B ZinmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.